In this edition of Biotech Banter, Motley Fool contributor Brian Orelli and health care bureau chief Max Macaluso discuss an FDA delay for MannKind's Afrezza, clinical trial results from Amgen's T-VEC, up-and-coming biotech Agios, and the biotech "Tweet of the Week."
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.